QianJin Pharmaceutical(SH:600479) CMS·2025-09-05 15:28Investment Rating - The report maintains an "Accumulate" investment rating for the company [3][7]. Core Views - The company achieved a revenue of 1.818 billion yuan in the first half of 2025, a year-on-year decrease of 5.52%, while the net profit attributable to shareholders increased by 8.50% to 128 million yuan [1][7]. - The pharmaceutical industry continues to grow steadily, with the company's pharmaceutical segment generating a revenue of 1.005 billion yuan, a year-on-year increase of 6.4% [7]. - The company is focusing on high-intensity R&D, with R&D expenses reaching 104 million yuan in the first half of 2025, maintaining a high investment pace [7]. Financial Performance - The company reported a gross margin of 49.97% in the first half of 2025, an increase of 4.80 percentage points year-on-year, driven by a higher proportion of high-margin business and a decrease in raw material costs [7]. - The net profit margin improved to 9.57%, up 1.82 percentage points year-on-year, indicating a clear recovery in profitability [7]. - The company expects net profits for 2025-2026 to be 292 million yuan, 366 million yuan, and 437 million yuan, representing year-on-year growth rates of 27%, 25%, and 19% respectively [7][10]. Financial Data and Valuation - The total revenue forecast for 2025 is 3.613 billion yuan, with a projected net profit of 292 million yuan [2][9]. - The company’s PE ratio is projected to be 15.6 for 2025, decreasing to 10.4 by 2027 [2][10]. - The company’s total assets are expected to reach 4.735 billion yuan by 2025, with total liabilities of 1.375 billion yuan [8][10].